OR WAIT null SECS
Cannuba has announced its support of the first national pilot study in the United Kingdom aimed at assessing patients on prescription medical cannabis.
Cannabis-based products company, Cannuba, has announced its support of the first national pilot study in the United Kingdom, Project TWENTY21, aimed at assessing the efficacy, safety, quality-adjusted life year, and patient reported outcomes of patients on prescription medical cannabis.
The goal of Project TWENTY21, which is run by the independent scientific body, Drug Science, is to enroll 20,000 patients before the end of 2021 through a real-world data patient registry. The pilot study will investigate specific uses of medical cannabis and will focus particularly on instances where alternative treatment has failed.
“We are very excited to be working with Drug Science on of this potentially policy changing project,” said Rob James, CEO of Cannuba, in a July 30, 2019 press release. “The study will be a great opportunity to collate scientific, tangible statistics for medical cannabis. It’s exciting to be at the forefront of meaningful scientific research taking place in the UK.”
This pilot study is part of the ongoing work by the Drug Science Cannabis Working Group, which launched at the House of Lords earlier in 2019.